Alkermes plc (ALKS)

NASDAQ: ALKS · IEX Real-Time Price · USD
24.07
+0.22 (0.92%)
At close: Apr 22, 2024, 4:00 PM
24.09
+0.02 (0.08%)
After-hours: Apr 22, 2024, 6:41 PM EDT
0.92%
Market Cap 4.02B
Revenue (ttm) 1.66B
Net Income (ttm) 355.76M
Shares Out 167.08M
EPS (ttm) 2.10
PE Ratio 11.46
Forward PE 8.37
Dividend n/a
Ex-Dividend Date n/a
Volume 1,543,005
Open 24.08
Previous Close 23.85
Day's Range 23.76 - 24.19
52-Week Range 22.01 - 33.71
Beta 0.55
Analysts Buy
Price Target 35.11 (+45.87%)
Earnings Date May 1, 2024

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su... [Read more]

Sector Healthcare
IPO Date Jul 16, 1991
Employees 2,100
Stock Exchange NASDAQ
Ticker Symbol ALKS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $35.11, which is an increase of 45.87% from the latest price.

Price Target
$35.11
(45.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alkermes to Report First Quarter Financial Results on May 1, 2024

DUBLIN , April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

5 days ago - PRNewsWire

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested in Both ...

13 days ago - PRNewsWire

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

DUBLIN , April 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS...

14 days ago - PRNewsWire

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

DUBLIN , March 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board).

6 weeks ago - PRNewsWire

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024

—  Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — —  GAAP Net Income of $356 Million and Diluted GAAP Earnings per Share of $2....

2 months ago - PRNewsWire

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024

DUBLIN , Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

2 months ago - PRNewsWire

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference

DUBLIN , Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42nd Annual J.P. M...

3 months ago - PRNewsWire

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)

— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment — DUBLIN , Jan. 3, ...

3 months ago - PRNewsWire

Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk

DUBLIN , Dec. 14, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Irelan...

4 months ago - PRNewsWire

Alkermes to Participate in Two Upcoming Investor Conferences

DUBLIN , Nov. 21, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Piper Sandler 3...

5 months ago - PRNewsWire

Alkermes Completes Separation of Oncology Business

—    Alkermes Emerges as Pure-Play, Profitable Neuroscience Company — —    Alkermes Provides Updated Financial Expectations for 2023 — DUBLIN , Nov. 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS...

5 months ago - PRNewsWire

Alkermes to Participate in the Jefferies London Healthcare Conference

DUBLIN , Nov. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 14,...

5 months ago - PRNewsWire

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

DUBLIN , Oct. 31, 2023  /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was d...

6 months ago - PRNewsWire

Alkermes plc Reports Third Quarter 2023 Financial Results

— Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income of $47.8 Million and Non-GAAP Net Income of $109.5 Million ...

6 months ago - PRNewsWire

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

—    Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 — —    ALKS 2680 Was Generally Well Tolerated at All Doses Tested...

6 months ago - PRNewsWire

Alkermes to Report Third Quarter Financial Results on October 25, 2023

DUBLIN , Oct. 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

6 months ago - PRNewsWire

Mural Oncology to Host Investor Webcast on October 17

—  Event to be Webcast on Tuesday, October 17 at 11:00 a.m. ET — DUBLIN , Oct. 10, 2023  /PRNewswire/ -- Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans...

6 months ago - PRNewsWire

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

— Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist — DUBLIN , Oct. 10, 2023...

6 months ago - PRNewsWire

Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

— Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy — DUBLIN , Sept. 11, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today ann...

8 months ago - PRNewsWire

Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program

—     Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project  — —    Application Period to Run From Sept. 15, 2023 Through Nov. 30, 2023  — DUBLIN , Sept.

8 months ago - PRNewsWire

Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program

– Competitive Grants Program Awards Funding to 11 Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer – DUBLIN , Aug. 31, 2023 /PRNewswire/ -- Alkermes plc (N...

8 months ago - PRNewsWire

Alkermes shares surge after settlement with Teva on alcohol dependence treatment

Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Teva Pharmaceuticals USA Inc. TEVA, relating to Vivit...

Other symbols: TEVA
8 months ago - Market Watch

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

— Company Grants Teva a License to Market Generic VIVITROL Beginning in January 2027 — DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc  (Nasdaq: ALKS) announced today that the company entered into ...

8 months ago - PRNewsWire

Alkermes plc Reports Second Quarter 2023 Financial Results

— Second Quarter Revenues of $617.4 Million Reflect Strong Performance of Proprietary Product Portfolio and Reinstatement of Long-Acting INVEGA® Product Royalties — — Net Sales of Proprietary Products...

9 months ago - PRNewsWire

Alkermes to Report Second Quarter Financial Results on July 26, 2023

DUBLIN , July 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

9 months ago - PRNewsWire